| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542944P | 2017-08-09 | 2017-08-09 | |
| PCT/US2018/045742WO2019032662A1 (en) | 2017-08-09 | 2018-08-08 | Clec9a binding agents and use thereof |
| Publication Number | Publication Date |
|---|---|
| SG11202001063QAtrue SG11202001063QA (en) | 2020-03-30 |
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11202001063QASG11202001063QA (en) | 2017-08-09 | 2018-08-08 | Clec9a binding agents and use thereof |
| Country | Link |
|---|---|
| US (3) | US12091463B2 (en) |
| EP (1) | EP3665303A4 (en) |
| JP (3) | JP7327885B2 (en) |
| KR (3) | KR102793204B1 (en) |
| CN (2) | CN117924493A (en) |
| AU (2) | AU2018313810B2 (en) |
| BR (1) | BR112020002706A2 (en) |
| CA (1) | CA3069992A1 (en) |
| IL (1) | IL272524A (en) |
| MX (3) | MX2020001513A (en) |
| SG (1) | SG11202001063QA (en) |
| WO (1) | WO2019032662A1 (en) |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3455245A2 (en)* | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| EP3596108A4 (en) | 2017-03-15 | 2020-12-23 | Pandion Operations, Inc. | TARGETED IMMUNTOLERANCE |
| BR112019024127A2 (en) | 2017-05-24 | 2020-06-23 | Pandion Therapeutics, Inc. | TARGETED IMMUNOTOLERANCE |
| US10946068B2 (en) | 2017-12-06 | 2021-03-16 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| USRE50550E1 (en) | 2017-12-06 | 2025-08-26 | Pandion Operations, Inc. | IL-2 muteins and uses thereof |
| US10174092B1 (en) | 2017-12-06 | 2019-01-08 | Pandion Therapeutics, Inc. | IL-2 muteins |
| CA3090406A1 (en) | 2018-02-05 | 2019-08-08 | Orionis Biosciences, Inc. | Fibroblast binding agents and use thereof |
| EP3841112A1 (en) | 2018-08-24 | 2021-06-30 | Codiak BioSciences, Inc. | Extracellular vesicles targeting dendritic cells and uses thereof |
| EP3849614B1 (en)* | 2018-09-11 | 2023-12-20 | Ambrx, Inc. | Interleukin-2 polypeptide conjugates and their uses |
| WO2020097350A1 (en) | 2018-11-08 | 2020-05-14 | Orionis Biosciences, Inc. | Modulation of dendritic cell lineages |
| CA3133831A1 (en) | 2019-03-28 | 2020-10-01 | Nikolai Kley | Clec9a-based chimeric protein complexes |
| JP7689079B2 (en) | 2019-03-28 | 2025-06-05 | オリオニス バイオサイエンシズ，インコーポレイテッド | Therapeutic interferon alpha 1 protein |
| US11739146B2 (en) | 2019-05-20 | 2023-08-29 | Pandion Operations, Inc. | MAdCAM targeted immunotolerance |
| US20220378925A1 (en)* | 2019-09-26 | 2022-12-01 | Orionis Biosciences, Inc. | Conjugated chimeric proteins |
| AU2020398327A1 (en) | 2019-12-03 | 2022-07-14 | Evotec International Gmbh | Interferon-associated antigen binding proteins and uses thereof |
| WO2021168079A1 (en) | 2020-02-21 | 2021-08-26 | Pandion Operations, Inc. | Tissue targeted immunotolerance with a cd39 effector |
| KR20210129489A (en) | 2020-04-20 | 2021-10-28 | 에스케이이노베이션 주식회사 | Battery module |
| IL301285A (en) | 2020-09-10 | 2023-05-01 | Precirix N V | A portion of an antibody against FAP |
| US12037399B2 (en) | 2020-10-07 | 2024-07-16 | Dren Bio, Inc. | Anti-Dectin-1 antibodies and methods of use thereof |
| WO2022163809A1 (en)* | 2021-01-29 | 2022-08-04 | Chugai Seiyaku Kabushiki Kaisha | Molecule specifically acting in a tissue where a cell death being observed |
| IL286430A (en) | 2021-09-14 | 2023-04-01 | Yeda Res & Dev | Multispecific antibodies for use in treating diseases |
| WO2023203135A1 (en) | 2022-04-22 | 2023-10-26 | Precirix N.V. | Improved radiolabelled antibody |
| CN114702588B (en)* | 2022-04-27 | 2022-11-22 | 博际生物医药科技(杭州)有限公司 | anti-Nectin-4 antibodies and bispecific antibodies |
| WO2023213801A1 (en) | 2022-05-02 | 2023-11-09 | Precirix N.V. | Pre-targeting |
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991002754A1 (en) | 1989-08-22 | 1991-03-07 | Immunex Corporation | Fusion proteins comprising gm-csf and il-3 |
| US6277969B1 (en) | 1991-03-18 | 2001-08-21 | New York University | Anti-TNF antibodies and peptides of human tumor necrosis factor |
| US5914254A (en) | 1993-08-02 | 1999-06-22 | Celtrix Pharmaceuticals, Inc. | Expression of fusion polypeptides transported out of the cytoplasm without leader sequences |
| US7101974B2 (en) | 2000-03-02 | 2006-09-05 | Xencor | TNF-αvariants |
| DK2206517T3 (en) | 2002-07-03 | 2023-11-06 | Ono Pharmaceutical Co | Immunopotentiating compositions comprising anti-PD-L1 antibodies |
| US20110020273A1 (en) | 2005-04-06 | 2011-01-27 | Ibc Pharmaceuticals, Inc. | Bispecific Immunocytokine Dock-and-Lock (DNL) Complexes and Therapeutic Use Thereof |
| EP1812038A1 (en) | 2004-11-18 | 2007-08-01 | VIB vzw | Fibronectin iii domain as leptin receptor antagonists |
| WO2006115800A2 (en) | 2005-04-15 | 2006-11-02 | The Regents Of The University Of California | Enhanced wound healing utilizing an anti-her2 antibody coupled to a tnf alpha |
| CA2693326A1 (en) | 2006-08-02 | 2008-02-07 | Mcgill University | Gm-csf and il-15 fusokines and methods for modulation of the immune response |
| US11535673B2 (en) | 2007-04-05 | 2022-12-27 | President and Fellows of Harvard CoHege | Chimeric activators: quantitatively designed protein therapeutics and uses thereof |
| WO2009003145A1 (en) | 2007-06-26 | 2008-12-31 | University Of Miami | Antibody-endostatin fusion protein and its variants |
| GB0805159D0 (en)* | 2008-03-19 | 2008-04-23 | Sancho Madrid David | Immune modulation via C-type lectin |
| JP5591701B2 (en) | 2007-09-21 | 2014-09-17 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | Targeted interferon with potent apoptotic and antitumor activity |
| US20110224407A1 (en) | 2008-09-09 | 2011-09-15 | University Of Medicine And Dentistry Of New Jersey | Type I Interferon Antagonists |
| US8334101B2 (en) | 2008-09-26 | 2012-12-18 | University Of Massachusetts | Intracellular DNA receptor |
| CA2749558C (en) | 2008-12-08 | 2019-01-15 | Complix Nv | Single-chain antiparallel coiled coil proteins |
| CN102361646A (en)* | 2009-03-23 | 2012-02-22 | 沃尔特及伊莱萨霍尔医学研究院 | Compounds and methods for modulating immune responses |
| WO2011020783A2 (en) | 2009-08-17 | 2011-02-24 | Roche Glycart Ag | Targeted immunoconjugates |
| AU2010294249A1 (en) | 2009-09-10 | 2012-05-03 | Cytos Biotechnology Ag | Use of interleukin-1 beta mutein conjugates in the treatment of diabetes |
| RU2577299C2 (en) | 2011-07-04 | 2016-03-10 | Олег Ильич Эпштейн | Method for treating infectious diseases and complex medication for treatment of infectious diseases |
| EP2718457A4 (en) | 2011-06-06 | 2014-12-24 | Immungene Inc | Engineered antibody-tnfsf member ligand fusion molecules |
| WO2013053008A2 (en) | 2011-10-14 | 2013-04-18 | The Walter And Eliza Hall Institute Of Medical Research | Molecules which bind clec9a |
| MX360741B (en) | 2011-10-28 | 2018-11-14 | Teva Pharmaceuticals Australia Pty Ltd | Polypeptide constructs and uses thereof. |
| AU2013211059B8 (en) | 2012-01-20 | 2017-12-21 | Centre Hospitalier Regional Universitaire De Montpellier | Targeted mutant alpha-helical bundle cytokines |
| US8980267B2 (en) | 2012-03-03 | 2015-03-17 | Immungene Inc | Engineered antibody-interferon mutant fusion molecules |
| WO2013163689A1 (en) | 2012-05-01 | 2013-11-07 | The University Of Sydney | Vaccine and uses thereof |
| AU2014249243C1 (en) | 2013-03-13 | 2019-08-08 | Imaginab, Inc. | Antigen binding constructs to CD8 |
| AU2014273418B2 (en)* | 2013-04-29 | 2020-04-23 | Biotalys NV | Agrochemical compositions comprising antibodies binding to sphingolipids |
| ITTO20130563A1 (en)* | 2013-07-05 | 2015-01-06 | Savio Spa | DEVICE FOR OPENING AND CLOSING AN OPCILLATING DOOR OPENING TOWARDS THE OUTSIDE |
| CN110835376B (en) | 2013-07-18 | 2023-08-04 | 弗拉芒区生物技术研究所 | Fusion factors involving cytokines with strongly reduced receptor binding affinities |
| BR112016001114B1 (en) | 2013-07-19 | 2023-02-14 | Vib Vzw | COMPOSITION COMPRISING A FUSION PROTEIN AND USE OF SUCH COMPOSITION |
| ES2714504T3 (en) | 2013-07-19 | 2019-05-28 | Vib Vzw | Directed modified il-1 family members |
| KR102305608B1 (en) | 2013-07-19 | 2021-09-28 | 브이아이비 브이지더블유 | Targeting of cytokine antagonists |
| BR112016002614B8 (en) | 2013-08-08 | 2023-11-07 | Hopitaux Paris Assist Publique | Immunocytokine and pharmaceutical composition |
| UA119352C2 (en) | 2014-05-01 | 2019-06-10 | Тева Фармасьютикалз Острейліа Пті Лтд | COMBINATION OF LENALIDOMIDE OR POMALIDOMIDE AND STRUCTURES OF ANTI-CD38 ANTIBODY-ATHENED INTERPHERONE ALPHA-2B AND METHOD OF TREATMENT38 |
| WO2016187459A1 (en)* | 2015-05-20 | 2016-11-24 | The Regents Of The University Of California | Method for generating human dendritic cells for immunotherapy |
| US11702477B2 (en) | 2015-11-06 | 2023-07-18 | Orionis Biosciences BV | Bi-functional chimeric proteins and uses thereof |
| CA3013551A1 (en)* | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Clec9a binding agents and use thereof |
| US11236141B2 (en) | 2016-05-13 | 2022-02-01 | Orionis Biosciences BV | Targeted mutant interferon-beta and uses thereof |
| EP3455245A2 (en) | 2016-05-13 | 2019-03-20 | Orionis Biosciences NV | Therapeutic targeting of non-cellular structures |
| CA3040802A1 (en)* | 2016-10-24 | 2018-05-03 | Orionis Biosciences Nv | Targeted mutant interferon-gamma and uses thereof |
| EP3576765B1 (en) | 2017-02-06 | 2025-07-16 | Orionis Biosciences, Inc. | Targeted engineered interferon and uses thereof |
| CN110546160A (en) | 2017-02-06 | 2019-12-06 | 奥里尼斯生物科学公司 | Targeted chimeric proteins and their uses |
| US11246911B2 (en) | 2017-02-07 | 2022-02-15 | Vib Vzw | Immune-cell targeted bispecific chimeric proteins and uses thereof |
| KR20210005872A (en)* | 2018-03-28 | 2021-01-15 | 오리오니스 바이오사이언시즈 인코포레이티드 | Bifunctional proteins and constructs thereof |
| Publication number | Publication date |
|---|---|
| CN111511764A (en) | 2020-08-07 |
| JP7746499B2 (en) | 2025-09-30 |
| JP2024178285A (en) | 2024-12-24 |
| EP3665303A4 (en) | 2021-04-28 |
| KR102659140B1 (en) | 2024-04-19 |
| WO2019032662A1 (en) | 2019-02-14 |
| US12091463B2 (en) | 2024-09-17 |
| US20210024637A1 (en) | 2021-01-28 |
| BR112020002706A2 (en) | 2020-08-25 |
| US20240360224A1 (en) | 2024-10-31 |
| MX2025009223A (en) | 2025-09-02 |
| AU2025203121A1 (en) | 2025-06-12 |
| AU2018313810B2 (en) | 2025-05-15 |
| KR20200047564A (en) | 2020-05-07 |
| MX2020001513A (en) | 2020-08-20 |
| AU2018313810A1 (en) | 2020-02-27 |
| CN117924493A (en) | 2024-04-26 |
| JP7327885B2 (en) | 2023-08-16 |
| CA3069992A1 (en) | 2019-02-14 |
| IL272524A (en) | 2020-03-31 |
| JP7559114B2 (en) | 2024-10-01 |
| KR20250049459A (en) | 2025-04-11 |
| JP2020530302A (en) | 2020-10-22 |
| MX2025009222A (en) | 2025-09-02 |
| KR102793204B1 (en) | 2025-04-08 |
| WO2019032662A8 (en) | 2020-03-05 |
| JP2023060153A (en) | 2023-04-27 |
| EP3665303A1 (en) | 2020-06-17 |
| CN111511764B (en) | 2024-02-06 |
| US20250066486A1 (en) | 2025-02-27 |
| KR20240055153A (en) | 2024-04-26 |
| Publication | Publication Date | Title |
|---|---|---|
| SG11202001063QA (en) | Clec9a binding agents and use thereof | |
| IL278888A (en) | Psma binding agents and uses thereof | |
| IL272643A (en) | Binding agents | |
| IL268206A (en) | Bcma-targeting antibody and use thereof | |
| IL264813B (en) | 2-oxo-imidazopyridines and their use | |
| IL287291A (en) | Rgma binding protein and use thereof | |
| LT3621694T (en) | Lrrc33 inhibitors and use thereof | |
| IL268288A (en) | Binding agents | |
| PT3544637T (en) | Nomv-antigen conjugates and use thereof | |
| SG11202003585VA (en) | Anti-vista antibody and use thereof | |
| ZA201906248B (en) | Anti-ceacam1 antibody and use thereof | |
| IL269836B (en) | Substituted n-arylethyl-2-aminoquinoline-4-carboxamides and use thereof | |
| IL265531A (en) | N 3 -cyclically substituted thienouraciles and use thereof | |
| IL280369A (en) | New myokines and uses thereof | |
| IL269843B (en) | Substituted n-arylethyl-2-arylquinoline-4-carboxamides and use thereof | |
| GB2562083B (en) | Fungicidal composition and use thereof | |
| GB201522829D0 (en) | Herbicidal composition and use thereof | |
| HK40031705A (en) | Clec9a binding agents and use thereof | |
| IL278919A (en) | Combinations comprising tropifexor and cenicriviroc | |
| IL284285A (en) | Domperidone antineurodegenerative combinations and use | |
| IL265617B (en) | 1-phenylpropanone compounds and use thereof | |
| GB201815215D0 (en) | Composition and use | |
| GB201713298D0 (en) | Binding agents | |
| GB201713296D0 (en) | Binding agents | |
| GB201712101D0 (en) | nOMV-ANTIGEN CONJUGATES AND USE THEREOF |